Patients with kidney cancer who took probiotic supplements of Clostridium butyricum had improved response to immunotherapy, according to a randomized phase 1 study.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mountzouris, K. C., McCartney, A. L. & Gibson, G. R. Br. J. Nutr. 87, 405–420 (2002).
Isa, K. et al. Hum. Exp. Toxicol. 35, 818–832 (2016).
Dizman, N. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01694-6 (2022).
Seki, H. et al. Pediatr. Int. 45, 86–90 (2003).
Stoeva, M. K. et al. Gut Microbes 13, 1–28 (2021).
Tomita, Y. et al. Cancer Immunol. Res. 8, 1236–1242 (2020).
Sivan, A. et al. Science 350, 1084–1089 (2015).
Thana, M. et al. Clin. Genitourin. Cancer https://doi.org/10.1016/j.clgc.2021.12.003 (2021).
Derosa, L. et al. Eur. Urol. 78, 195–206 (2020).
Salgia, N. J. et al. Eur. Urol. 78, 498–502 (2020).
Spencer, C. N. et al. Science 374, 1632–1640 (2021).
Derosa, L. et al. Cancer Discov. 11, 2396–2412 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L.D. declares consulting and advisory role fees from BMS, Sanofi, Astra Zeneca and was supported by Philantropia Fondation Gustave Roussy. L.Z. received research contract from Kaleido, Innovate Pharma and Pilege.
Rights and permissions
About this article
Cite this article
Derosa, L., Zitvogel, L. A probiotic supplement boosts response to cancer immunotherapy. Nat Med 28, 633–634 (2022). https://doi.org/10.1038/s41591-022-01723-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01723-4